To include your compound in the COVID-19 Resource Center, submit it here.

Top shelf cocktail mixers

Vertex picks polymerase inhibitors from Alios to build all-oral HCV cocktail

With an eye to creating an all-oral, interferon-free cocktail to treat HCV, Vertex Pharmaceuticals Inc. licensed a pair of complementary nucleotide HCV NS5B polymerase inhibitors from Alios BioPharma Inc. that have shown best-in-class potential in the lab for suppressing viral resistance.

The immediate benefit from FDA's recent approval of Vertex's Incivek telaprevir and Merck & Co. Inc.'s Victrelis boceprevir - a pair of HCV NS3/4A protease inhibitors - is that patients

Read the full 706 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE